Elevated Prevalence of Abnormal Glucose Metabolism and Other Endocrine Disorders in Patients with -Thalassemia Major: A Meta-Analysis

Table 2

Prevalence of abnormal glucose metabolism and other endocrine disorders in β-thalassemia major classified by study region.

Region	DM		IFG		IGT		EnD
	P (%)	95% CI (%)	P (%)	95% CI (%)	P (%)	95% CI (%)	P (%)	95% CI (%)
Mediterranean coast	5.36	3.95-6.77	6.52	5.74-7.30	15.16	3.56-26.76	39.82	33.55-46.10
Middle East	7.90	5.75-10.05	27.88	18.50-37.26	7.14	0.13-14.15	36.67	31.22-42.11
Europe	6.05	2.82-9.28	NR	NR	14.01	8.56-19.45	65.98	56.61-75.35
America	12.77	7.24-18.31	NR	NR	NR	NR	27.50	24.67-30.32
Asia	6.38	2.75-10.01	18.29	5.67-30.91	9.07	4.97-13.16	55.06	44.80-65.32
Oceania	18.18	6.78-29.58	NR	NR	NR	NR	NR	NR
Overall	6.54	5.30-7.78	17.21	8.43-26.00	12.46	5.98-18.94	43.92	37.94-49.89

DM: diabetes mellitus; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; EnD: endocrine disorders; P: prevalence; 95% CI: 95% confidence interval; NR: not reported.